Analyst Price Target is $39.34
▲ +448.71% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Fresenius SE & Co. KGaA in the last 3 months. The average price target is $39.34, with a high forecast of $87.00 and a low forecast of $24.00. The average price target represents a 448.71% upside from the last price of $7.17.
Current Consensus is
The current consensus among 12 polled investment analysts is to buy stock in Fresenius SE & Co. KGaA. This rating has held steady since November 2021, when it changed from a Hold consensus rating.
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment caters to individuals with renal diseases. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany.